HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bernard Le Foll Selected Research

Buspirone (Buspar)

1/2019Pharmacotherapies for cannabis dependence.
11/2017The effects of buspirone on occupancy of dopamine receptors and the rat gambling task.
1/2016Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.
7/2014Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone.
1/2014Pharmacotherapies for cannabis dependence.
3/2013Repurposing buspirone for drug addiction treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bernard Le Foll Research Topics

Disease

34Tobacco Use Disorder (Nicotine Dependence)
01/2021 - 04/2005
29Substance-Related Disorders (Drug Abuse)
01/2022 - 01/2005
12Alcoholism (Alcohol Abuse)
01/2022 - 12/2011
12Schizophrenia (Dementia Praecox)
01/2019 - 01/2005
11Opioid-Related Disorders (Opiate Addiction)
10/2022 - 01/2015
9Marijuana Abuse (Cannabis Abuse)
01/2020 - 01/2008
8Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/2019 - 03/2006
7Mental Disorders (Mental Disorder)
05/2021 - 12/2011
6Obesity
12/2021 - 07/2009
5Gambling (Pathological Gambling)
01/2018 - 01/2015
4Anxiety Disorders (Anxiety Disorder)
01/2021 - 07/2014
3Social Phobia
04/2022 - 01/2019
3Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
01/2022 - 10/2017
3Pain (Aches)
01/2022 - 01/2021
3Confusion (Bewilderment)
01/2022 - 01/2020
3Weight Loss (Weight Reduction)
01/2020 - 05/2013
2COVID-19
01/2022 - 01/2022
2Body Weight (Weight, Body)
01/2020 - 01/2015
2Psychotic Disorders (Schizoaffective Disorder)
03/2019 - 06/2012
2Mood Disorders (Mood Disorder)
01/2019 - 04/2011
2Acquired Immunodeficiency Syndrome (AIDS)
10/2018 - 04/2005
2Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2013 - 07/2009
2Hypersensitivity (Allergy)
11/2010 - 03/2003
1Hypogonadism (Hypergonadotropic Hypogonadism)
10/2022
1Opiate Overdose
10/2022
1Drug Overdose
01/2022
1Cancer Pain
01/2022
1Acute Pain
01/2022
1Major Depressive Disorder (Major Depressive Disorders)
12/2021
1Chronic Pain
08/2021
1Wounds and Injuries (Trauma)
05/2021
1Genetic Risk Score
01/2021
1Liver Diseases (Liver Disease)
01/2021
1Brain Diseases (Brain Disorder)
01/2020
1Narcolepsy
01/2020
1Psychomotor Disorders
01/2020
1Fatigue
01/2020

Drug/Important Bio-Agent (IBA)

21Pharmaceutical PreparationsIBA
10/2022 - 04/2005
19NicotineFDA Link
01/2021 - 04/2005
15CannabinoidsIBA
01/2022 - 03/2005
13EndocannabinoidsIBA
01/2022 - 11/2008
11Opioid Analgesics (Opioids)IBA
10/2022 - 04/2007
11LigandsIBA
12/2020 - 03/2005
11Dopamine (Intropin)FDA LinkGeneric
12/2020 - 03/2003
9Dronabinol (THC)FDA LinkGeneric
01/2020 - 05/2013
8Dopamine D3 ReceptorsIBA
11/2021 - 01/2005
7EnzymesIBA
12/2021 - 10/2014
7Varenicline (Chantix)FDA Link
03/2020 - 01/2007
6RimonabantIBA
01/2020 - 06/2008
6Buspirone (Buspar)FDA LinkGeneric
01/2019 - 03/2013
6Bupropion (Wellbutrin)FDA LinkGeneric
01/2019 - 04/2005
4Methadone (Dolophine)FDA LinkGeneric
10/2022 - 01/2018
4fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA
12/2021 - 08/2015
4CannabidiolIBA
01/2020 - 05/2013
4CB1 Cannabinoid Receptor (CB1 Receptor)IBA
01/2020 - 03/2005
3Naloxone Drug Combination BuprenorphineFDA Link
10/2022 - 01/2018
3Peroxisome Proliferator-Activated Receptors (PPAR)IBA
12/2020 - 06/2013
3Antidepressive Agents (Antidepressants)IBA
01/2019 - 04/2005
3Antipsychotic Agents (Antipsychotics)IBA
01/2019 - 11/2012
3Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2018 - 01/2014
3Brain-Derived Neurotrophic Factor (BDNF)IBA
04/2015 - 07/2010
3SmokeIBA
03/2015 - 09/2011
3Cocaine (Cocaine HCl)IBA
11/2012 - 02/2008
2Histamine H3 Receptors (Histamine H3 Receptor)IBA
01/2022 - 01/2020
2Ethanol (Ethyl Alcohol)IBA
01/2022 - 07/2014
2Biological ProductsIBA
01/2022 - 01/2020
2Lysergic Acid Diethylamide (LSD)IBA
01/2022 - 05/2021
23,4-methylenedioxyethamphetamine (MDEA)IBA
01/2021 - 12/2011
2Disulfiram (Antabuse)FDA Link
01/2019 - 01/2018
2Anti-Anxiety Agents (Anxiolytics)IBA
01/2019 - 01/2014
2Naltrexone (ReVia)FDA LinkGeneric
01/2019 - 01/2016
2Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric
01/2019 - 01/2014
2nabiximols (Sativex)IBA
01/2018 - 07/2016
2Dopamine Receptors (Dopamine Receptor)IBA
11/2017 - 02/2009
2AM4113IBA
12/2016 - 01/2016
2Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
03/2016 - 11/2010
2Opiate AlkaloidsIBA
01/2016 - 04/2007
2Adrenergic Receptors (Adrenergic Receptor)IBA
07/2010 - 04/2007
1Fentanyl (Sublimaze)FDA LinkGeneric
10/2022
1Protons (Proton)IBA
04/2022
1Lipoprotein Lipase (Diacylglycerol Lipase)IBA
12/2021
1Monoacylglycerol LipasesIBA
12/2021
1Medical MarijuanaIBA
08/2021
1N,N-Dimethyltryptamine (Dimethyltryptamine)IBA
05/2021
1Hallucinogens (Psychedelics)IBA
05/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1Biomarkers (Surrogate Marker)IBA
01/2021
1Dopamine D4 Receptors (Dopamine D4 Receptor)IBA
01/2020
1MelatoninIBA
01/2020
1Indicators and Reagents (Reagents)IBA
01/2020
1pitolisantIBA
01/2020
1Therapeutic UsesIBA
01/2020

Therapy/Procedure

9Drug Therapy (Chemotherapy)
01/2020 - 11/2007
5Therapeutics
10/2022 - 07/2016
4Nicotine Replacement Therapy
06/2020 - 04/2005
2Transcranial Magnetic Stimulation
12/2021 - 12/2016
2Injections
01/2021 - 09/2019
1Liver Transplantation
01/2021
1Precision Medicine
01/2021
1Continuity of Patient Care
01/2021